Skip to main content

Table 1 MCDA EVIDEM framework version 4.0 adapted to evaluation of medicines indicated for rare diseases

From: Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

QUANTITATIVE CRITERIA: MCDA Core Model
DOMAIN: Disease needs
 Disease severity
 Unmet needs
DOMAIN: Comparative outcomes of interventions (selexipag vs iloprost)
 Comparative efficacy/effectiveness
 Comparative safety/tolerability
 Comparative patient-perceived health/patient reported outcomes (PRO)
DOMAIN: Type of benefit provided by selexipag
 Type of preventive benefit
 Type of therapeutic benefit
DOMAIN: Comparative economic consequences of interventions (selexipag vs iloprost)
 Comparative cost of intervention
 Comparative other medical costs
 Comparative other non-medical costs
DOMAIN: Knowledge about selexipag
 Quality of evidence
 Expert consensus/clinical practice guidelines (CPG)
CONTEXTUAL CRITERIA: MCDA Contextual Tool
Population priorities and access
Common goals and specific interests
System capacity and appropriate use of intervention
Opportunity costs and affordability